Apyx Medical Reports 32.4% Revenue Growth to $12.5 Million in Q1 2026

Apyx Medical Corporation reported a significant increase in financial performance for the first quarter of 2026, with net sales reaching $12.5 million, a 32.4% increase compared to $9.4 million in the same period of 2025. The growth was primarily driven by a 36.1% rise in the Surgical Aesthetics segment, which generated $10.7 million in sales, attributed to the commercial launch of the AYON Body Contouring System and increased international sales of generators and single-use handpieces. The company's gross profit also improved, rising 39.9% to $7.9 million, resulting in a gross margin of 63.5%, up from 60.1% in the prior year.

Despite the revenue growth, Apyx Medical reported a net loss of $2.1 million for the quarter, a reduction from a net loss of $4.2 million in the first quarter of 2025. The decrease in losses was attributed to improved sales performance and a reduction in operating expenses, including a 4.9% decrease in research and development costs. The company’s total liabilities decreased to $49.9 million from $52.0 million at the end of 2025, while total stockholders' equity fell to $13.1 million from $14.8 million, reflecting ongoing operational challenges and the need for additional capital.

Operationally, Apyx Medical has focused on expanding its market presence, with international sales accounting for approximately 35.1% of total revenues in the first quarter, up from 28.5% in the previous year. The company has sold products in over 60 countries, supported by its facilities in Clearwater, Florida, and Sofia, Bulgaria. The Surgical Aesthetics segment's sales were bolstered by the sale of approximately 26,000 handpiece units, compared to 19,000 units in the same quarter of 2025. The company anticipates continued growth in this segment, particularly with the expected FDA clearance for the AYON Body Contouring System's label expansion to include power liposuction in the second quarter of 2026.

Looking ahead, Apyx Medical plans to fund its operations through existing cash reserves, product sales, and potential additional equity or debt financing. The company has acknowledged the challenges posed by ongoing net losses and cash outflows, which it expects to continue in the near term. Management has indicated that if additional financing is not secured, it may need to limit or reduce sales, marketing, and product development efforts, which could adversely affect its business operations and future prospects. The company remains committed to navigating these challenges while pursuing growth opportunities in the surgical aesthetics market.